Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 12/20 | 0.48 |
| ▸ | CTSL | P07711 | 5/20 | 0.35 |
| ▸ | CTSK | P43235 | 10/20 | 0.35 |
| ▸ | CTSB | P07858 | 8/20 | 0.35 |
| ▸ | CTSC | P53634 | 2/20 | 0.33 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4838374 | 0.88 | CTSS (0.52) | CTSSCTSLCTSKCTSBCTSC | |
| SCHEMBL6062590 | 0.88 | CTSS (0.52) | CTSSCTSLCTSKCTSBCTSC | |
| SCHEMBL4835668 | 0.85 | CTSS (0.63) | CTSSCTSLCTSKCTSBCTSC | |
| SCHEMBL4834550 | 0.85 | CTSS (0.63) | CTSSCTSLCTSKCTSBCTSC | |
| SCHEMBL13985857 | 0.81 | CTSS (0.77) | CTSSCTSLCTSKCTSB | |
| SCHEMBL13985859 | 0.81 | CTSS (0.77) | CTSSCTSLCTSKCTSB | |
| SCHEMBL7072668 | 0.75 | CTSS (0.41) | CTSSCTSLCTSKCTSBCTSC | |
| SCHEMBL7076976 | 0.74 | CTSS (0.40) | CTSSCTSLCTSKCTSBCTSC | |
| SCHEMBL7078199 | 0.74 | CTSS (0.40) | CTSSCTSLCTSKCTSBCTSC | |
| SCHEMBL5357550 | 0.73 | CTSS (0.42) | CTSSCTSLCTSKCTSBCTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465745-B2 | Cathepsin S inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-20050222145-A1 | Cathepsin S inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222145-A1 | Cathepsin S inhibitors | CTSS, CTSB, CTSZ | CTSS 1/4885CTSL 10/4885CTSK 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.